Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial.
Osman ÖcalKerstin SchütteJuozas KupčinskasEgidijus MorkunasGabija JurkeviciuteEnrico N de ToniNajib Ben KhaledThomas BergPeter MalfertheinerHeinz Josef KlümpenChristian SengelBristi BasuJuan W ValleJulia BenckertAntonio GasbarriniDaniel PalmerRicarda SeidenstickerMoritz WildgruberBruno SangroMaciej PechJens RickeMax SeidenstickerPublished in: Journal of cancer research and clinical oncology (2021)
IL-6 and IL-8 baseline values predicted outcomes of sorafenib-treated patients in this well-characterized prospective cohort of the SORAMIC trial. We suggest that the respective cut-off values might serve for validation in larger cohorts, potentially offering guidance for improved patient selection.